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Abstract
A number of autoimmune and other diseases have well established HLA associations; in many cases
there is strong evidence for the direct involvement of the HLA class II peptide-presenting antigens,
e.g., HLA DR-DQ for type 1 diabetes (T1D) and HLA-DR for rheumatoid arthritis (RA). The
involvement of additional HLA region genes in the disease process is implicated in these diseases.
We have developed a model-free approach to detect these additional disease genes using genotype
data; the conditional genotype method (CGM) and overall conditional genotype method (OCGM)
use all patient and control data and do not require haplotype estimation. Genotypes at marker
genes in the HLA region are stratified and their expected values are determined in a way that
removes the effects of linkage disequilibrium (LD) with the peptide-presenting HLA genes directly
involved in the disease. A statistic has been developed under the null hypothesis of no additional
disease genes in the HLA region for the OCGM method and was applied to the Genetic Analysis
Workshop 15 simulated data set of Problem 3, which mimics RA (answers were known). In
addition to the primary effect of the HLA DR locus, the effects of the other two HLA region
simulated genes involved in disease were detected (gene C, 0 cM from DR, increases RA risk only
in women; and gene D, 5.12 cM from DR, rare allele increases RA risk five-fold). No false negatives
were found. Power calculations were performed.
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Background
Features of complex genetic diseases showing HLA associ-
ations, such as incomplete penetrance, multiple disease-
predisposing loci both within and outside the HLA
region, heterogeneity, and interaction effects, make deter-
mination of their genetic basis more difficult than for
traits showing classic monogenic Mendelian inheritance.
Nonetheless, the direct involvement of HLA class II, and
in some cases class I, genes in the disease process has been
well documented for a number of complex diseases. Many
of these diseases are of autoimmune origin, but cancers,
infectious, and other diseases are also included. The issue
of contributions to these diseases by other HLA region
genes has been of interest for a number of years. Many
reports of other associations within the HLA region have
appeared in the literature. However, in many of these
studies it has been difficult to determine whether an addi-
tional HLA region gene is involved in disease, versus the
association's reflecting linkage disequilibrium (LD) with
the peptide-presenting HLA molecules directly involved
in disease.
A number of analytic strategies have been developed to
remove the effects of LD with the peptide-presenting HLA
genes directly involved in the disease. These include
matched genotype strategies [1], and for family-based
data the homozygous parent transmission disequilibrium
test (HPTDT) [2] and the homozygous parent linkage test
(HPLT) for affected sib pairs [3]. These three approaches
only use a subset of the patient and control data. The hap-
lotype method (henceforth referred to as the conditional
haplotype method (CHM)) [4-6] and the conditional
extended TDT (CETDT) [7,8] use more of the data, but
haplotypes need to be estimated. The logic of the CHM
starts with the assumption that all HLA genes directly
involved in disease susceptibility have been identified,
e.g., HLA DR in RA. We then examine the relative frequen-
cies of alleles at marker loci (e.g., single-nucleotide poly-
morphisms (SNPs), microsatellite markers, or other
classical HLA loci) located on specific haplotypes stratified
(to remove the effects of LD) by HLA DR in the case of RA,
e.g., the high risk DRB1*0401 allele. Under the null
hypothesis, the relative frequencies of the marker alleles
on these stratified haplotypes should be the same in cases
and controls. While fit to these expectations does not
exclude the possibility that other genes in the HLA com-
plex are involved in disease, lack of fit unequivocally
shows that all disease-predisposing genes in the region
have not been identified (provided that population strati-
fication effects, for example, have not produced spurious
results). The CHM tests for effects on individual haplo-
types at the primary disease predisposing locus. Thomson
[9] extended the CHM approach with development of a
method to test for additional genetic effects over all haplo-
types, henceforth referred to as the overall conditional
haplotype method (OCHM). One advantage of the CHM,
OCHM, and CETDT is that more of the data is used than
with the matched genotype approach and the HPTDT and
HPLT methods. However, care must be taken in all analy-
ses and their interpretations with rare haplotypes and
sparse cells.
Our aim in this study is to present a conditional genotype
approach that tests for the presence of additional disease
genes in a genetic region while accounting for LD with a
primary disease gene. In the conditional genotype
method (CGM), marker genotype frequencies are com-
pared between cases and controls (AFBACs (affected fam-
ily-based controls) in the case of family data [10,11]). Our
concentration in this paper is on the overall conditional
genotype method (OCGM) in which genotype frequen-
cies at marker loci are considered over all genotypes at the
primary disease locus (in fact only all common genotypes
are considered). We have developed an appropriate test
statistic and applied this method to the Genetic Analysis
Workshop 15 (GAW15) Problem 3 data (with answers
known).
Methods
Model
Let A be the primary disease locus of interest, with pene-
trance value wij for genotype AiAj. Under the null hypoth-
esis, the B locus is neutral with respect to disease and the
A locus accounts for all disease risk in this genetic region.
The frequencies of genotypes in controls at the A locus are
denoted fc(AiAj) and fp(AiAj) for patients. The expected
genotype frequencies among patients are given by:
fp(AiAj) = wijfc(AiAj)/T,
where T is a normalizing factor. No assumption of Hardy
Weinberg proportions in controls or patients is needed.
Rewriting Eq. (1a), the relative penetrance values are esti-
mated as follows:
wij /T = fp(AiAj)/fc(AiAj).
Adding the second neutral locus B, the expected two-locus
genotype frequencies under the null are given by:
exp fp(AiAjBkBl) = wij fc(AiAjBkBl)/T,
and substituting from Eq. (1b) gives
exp fp(AiAjBkBl) = fc(AiAjBkBl) [fp(AiAj)/fc(AiAj)].
Conditional genotype method (CGM)
For a given AiAj genotype, the term in [.] in Eq. (2b) is con-
stant, so under the null that the A locus is the only disease-
predisposing gene in the region, the relative genotype fre-BMC Proceedings 2007, 1(Suppl 1):S163 http://www.biomedcentral.com/1753-6561/1/S1/S163
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quencies at the B locus should show no heterogeneity
between patients and controls. We term this the condi-
tional genotype method (CGM), with analogy to the con-
ditional haplotype method (CHM) discussed above. In
both cases, statistical testing can be done via a chi-square
test of heterogeneity, with all the associated caveats
therein, Fisher's exact test, or a resampling approach. We
have not pursued this approach in the current analyses.
Overall conditional genotype method (OCGM)
If the effect of an additional disease-predisposing gene in
the region, e.g., the B gene or one in LD with it, is not spe-
cific to a particular haplotype or genotype at the primary
disease locus A, then more power should be available by
considering B locus genotypes combined over all A locus
genotypes. In this case, the expected genotype frequencies
at the B locus under the null hypothesis, assuming that A
(disease locus) segregates for m alleles and B (putative
neutral locus) for n alleles, are given by:
The question of statistical testing then arises. Application
of a standard test of homogeneity of the B  genotype
observed (obs) and expected (exp) numbers does not give
a chi-square distribution, in fact the distribution is expo-
nential. This is due to the use of the fp(AiAj)/fc(AiAj) ratio
in the estimation of expected values. This observation led
to the test statistic suggested below [12]. Note also that the
use of low-frequency control genotype frequencies
(fc(AiAj)) could be problematic notwithstanding and
these should be left out of any analyses, although this was
not necessary in the current analysis of simulated data.
We propose the following test statistic when comparing
exp fp(AiAjBkBl) to the observed value fp(AiAjBkBl) in our
statistical testing. For consistency we will refer to the latter
as obs fp(AiAjBkBl):
where:
and exp fp(BhBk) is given by Eq. (3). Note that no LD or
haplotype estimates are needed. With respect to analyses
of the GAW15 Problem 3 data we discuss power issues in
the Results section below and show that this test statistic
has the nominal p-value for markers with no effect on dis-
ease and not in LD with loci C and D.
Results
On the simulated RA-like Problem 3 data we used one
affected sib from all families (n = 1500) and all unrelated
controls (n = 2000) and studied 674 SNPs on chromo-
some 6. First we tested for genotype associations of each
SNP with disease, and found significant effects around the
HLA region (Figure 1A); however the DR and C locus
effects were intertwined. We then concentrated on SNPs
100–200 (the HLA region) in 50 replicates. A number of
SNPs showed associations, and these correlated with esti-
mated LD with the HLA DR4 allele simulated in the data
(allele 3 of the simulation) (Figure 1B and 1C). Significant
LD with DR4 extends from SNP 119 to 183, although
except for these two extremes, the significant LD falls
between SNPs 129 to 155.
Applying the OCGM to the data, the effects of Locus C and
Locus D, additional to those of HLA-DR were found (Fig-
ure 1D). The statistical power to detect the D locus was
higher, given that we only looked at the complete sample
without stratifying by gender with respect to Locus C.
However, for Loci C and D loci the power was greater than
80% at the p < 0.05 level and the type I error observed for
markers outside the main LD region with DR, C, or D are
consistent with theoretical expectations (Table 1). We
note that the type I error for markers 100 to 130 is slightly
higher than the nominal 5% and 1% because a few mark-
ers are in significant LD with DR.
Conclusion
We have developed a simple but powerful approach using
genotypes (the conditional genotype method (CGM) and
overall conditional genotype method (OCGM) method)
to detect association of a secondary locus in LD with a
major disease locus that is model free and does not
require estimation of haplotype frequencies. Even with
strong LD as seen with the DR and C loci in this data set,
we were able to detect the effect of the C locus after allow-
ing for the effect of the primary DR locus. This was possi-
ble even though D' = 1 for these two loci, as both alleles C
and c occur with allele DRX. In this case DRX refers to all
alleles that are not DR4 and not DR1, namely, allele 1 of
the simulation for the DR locus. The allele frequencies of
these two haplotypes were 0.15 and 0.50, respectively.
This allowed discrimination between risk effects of the
genotypes comprising these two haplotypes, and hence
detection of the C locus effect once the primary effect of
the DR locus was taken into account. The only situation in
which the CGM and OCGM, as well as other methods,
would not be useful is when there is an absolute 100%
correlation between all alleles at both loci. In such cases,
cross ethnic studies may be useful in that the LD pattern
may differ and not show 100% correlation.
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One could also take the observed (obs) and expected
(exp)  fp(BhBk) values from Eq. 3 and consider the
observed and expected allele frequencies at the B locus
under the null; obtained simply by the method of allele
(gene) counting. In effect, this is the same as the overall
conditional haplotype method (OCHM) [9] but the gen-
otype approach obviates the need to estimate LD values in
controls between the A and B genes as proposed in its ini-
tial implementation. Another difference is that whereas
the genotype-based implementation uses ratios of A locus
genotype frequencies in patients versus controls, the hap-
lotype-based implementation as originally proposed uses
allele frequencies. The effect of this on type I and type II
errors is not known and further work would be required
Genetic association, linkage disequilibrium and application of conditional genotype analysis to chromosome 6 simulated data Figure 1
Genetic association, linkage disequilibrium and application of conditional genotype analysis to chromosome 6 
simulated data. A, Genotype associations of HLA region (chromosome 6) SNPs; B, linkage disequilibrium of SNPs 100 to 200 
with the HLA DR4 allele; C, physical distribution of significant LD with chromosome 6 SNPs; D, application of the overall con-
ditional genotype method (OCGM) to the HLA region data. Results refer to the average of 50 simulation replicates.Publish with BioMed Central    and   every 
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to determine the appropriate test statistic for the OCHM
or a resampling approach could be applied. Thus, we have
shown theoretically how allele frequency data can also be
tested without resorting to estimation of haplotype fre-
quencies using the OCHM. The OCHM has not been
applied in this current research.
Our theory, applied to GAW15 Problem 3 data, and
power analyses of the OCGM, as well as discussion of the
CGM, CHM, and OCHM, show the utility of all these
approaches for detecting additional disease genes in LD
with a primary disease gene in a genetic region. Addition-
ally, all of these methods are useful in detecting primary
disease-predisposing genes in a region if they are not
known. Also, they can be used in across-genome studies to
detect the effects of other disease genes that have risk
effects that are not strictly multiplicative with a primary
disease gene under study, and hence the effects may be
easier to detect in samples stratified by the genotypes of
the primary disease gene.
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Table 1: Statistical power to detect Locus C and D effects using the overall conditional genotype method (OCGM) based on 50 
simulation replicates
Markera Disease locus p < 0.05 p < 0.01
100–139 none 6.0% 2.1%
152 C 24.0% 4.0%
153 DR 0.0% 0.0%
154 C 98.0% 72.0%
160 D 72.0% 50.0%
162 D 96.0% 94.0%
170–200 none 5.3% 1.2%
aThe average for markers number 100–139 and 170–200 is also shown.